Alzamed

Quick links to important sections

Alzamed

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alzamed

What is Alzamed? A Definitive Overview

Alzamed is a prescription-only medication whose active substance is Donepezil hydrochloride. It is a synthetic, small molecule compound, chemically derived as a piperidine derivative, designed to act centrally within the nervous system.

Property Description
Active ingredient Donepezil hydrochloride
Form Tablet, Orally Disintegrating Tablet (ODT), Transdermal Patch
Pharmacological class Cholinesterase Inhibitor
Common use Symptomatic support for memory and thinking
Origin Synthetic, Piperidine derivative

What Pharmacological Class Does Donepezil Belong To?

Donepezil is categorized as a Cholinesterase Inhibitor (ChEI), a pharmacological class widely recognized in clinical practice for influencing neurotransmission. This classification is based on the compound's defining action: the selective and reversible inhibition of the acetylcholinesterase enzyme (AChE) in the brain. Donepezil functions as a Cholinesterase Inhibitor, focusing on managing symptoms where cholinergic activity is diminished. This action shows the medicine is intended to support existing communication pathways in the brain.

Composition and Available Formats

The singular active ingredient of Alzamed is Donepezil hydrochloride. This compound is unique among some related agents for its long half-life, which supports its standard once-daily dosing profile. Donepezil is manufactured as a single-component product but is also available as a fixed-dose combination with Memantine for use in certain therapeutic strategies. Its pharmaceutical preparations include the conventional oral tablet, the quick-dissolving orally disintegrating tablet (ODT), and a transdermal patch system, which allows for either oral or transdermal delivery.

General Therapeutic Purpose

The fundamental objective of Donepezil therapy is to provide symptomatic relief by enhancing cholinergic transmission in the brain, thereby supporting cognitive functions such as memory and attention. By increasing the functional concentration of acetylcholine, the medication aims to optimize the remaining activity of nerve cells critical to these processes. It is recognized that Donepezil does not cure the underlying disease progression but helps manage symptoms. This means the treatment offers supportive management but is not intended to halt the underlying pathology.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Alzamed?

Possible Side Effects and Safety Information

Category Description based on Official Regulatory Data
Adverse reaction scope Gastrointestinal disturbances (Nausea, Diarrhoea), Neurological effects (Headache, Insomnia, Dizziness), Psychiatric effects (Hallucinations, Agitation), and Cardiac conduction issues (Bradycardia, Block) are key adverse reaction categories listed in official documents.
Frequency classification Very Common (more than 1 in 10 patients) effects include Nausea, Diarrhoea, and Headache. Common effects (up to 1 in 10) include Vomiting, Insomnia, Dizziness, Syncope (fainting), Muscle cramps, Anorexia, and Accidents (including falls).
System-organ classes involved Adverse reactions are grouped by affected systems, including Gastrointestinal disorders (e.g., ulcers, haemorrhage), Nervous system disorders (e.g., Seizure, Extrapyramidal symptoms), Cardiac disorders (e.g., Bradycardia, Heart Block), and Hepatobiliary disorders (e.g., Liver dysfunction, Hepatitis).
Serious adverse reactions Officially documented serious adverse events include Gastrointestinal haemorrhage and ulcer disease, Seizures, clinically significant Bradycardia and Heart Block (Sino-atrial block, Atrioventricular block), Neuroleptic malignant syndrome, Rhabdomyolysis, and the risk of QTc interval prolongation and Torsade de Pointes.
Population-specific safety considerations A similar dose schedule may be followed for patients with Renal Impairment. For Mild to Moderate Hepatic Impairment, dose escalation should be performed according to individual tolerability. No official data are available for patients with Severe Hepatic Impairment. Use is not recommended in the Pediatric Population (under 18 years).
Dose- or exposure-related patterns Common effects like Nausea, Vomiting, and Diarrhoea are reported to appear more frequently at the initiation of treatment and following dose increases. These events are often transient and may resolve with continued use.
Safety-related restrictions or limitations The medicine is Contraindicated in patients with known hypersensitivity to Donepezil hydrochloride or to piperidine derivatives. Caution is required in patients with a history of asthma or other obstructive pulmonary disease, or with pre-existing cardiac conduction abnormalities.

Connection to the Overall Safety Profile

The official safety data structures the understanding of risk by differentiating between the expected, time-limited very common effects (Nausea, Diarrhoea, Headache) and the formally documented uncommon to very rare, serious adverse reactions (Heart block, Seizures, GI Bleeding). This classification by frequency and system-organ class, as defined by regulatory documents, provides a clear, non-advisory framework for comprehending the complete risk landscape of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Alzamed (Donepezil hydrochloride) can lead to manifestations consistent with a cholinergic crisis, resulting from excessive acetylcholinesterase inhibition. Regulatory authorities document these manifestations at a high level, requiring immediate emergency response.

Documented Overdose Manifestations

System Official Signs and Symptoms
Cardiovascular Slow heartbeat (bradycardia), low blood pressure (hypotension), heart block, collapse.
Muscarinic Severe nausea and vomiting, increased salivation, sweating, and drooling.
Neurological/Muscular Convulsions (seizures), confusion, somnolence, and increasing muscle weakness.

Required Emergency Actions

Overdose is classified as potentially life-threatening due to risks of respiratory depression and muscle weakness. Regulatory guidance mandates that individuals seek immediate medical attention or get emergency help at once for a suspected overdose. Urgent medical services must be contacted immediately if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Management and Monitoring

The official management protocol includes symptomatic and supportive treatment. The label documents the use of anticholinergics such as Atropine (administered intravenously) as the antidote. Due to the risk of cardiac effects, continuous hospital monitoring is required for assessment of cardiac conduction abnormalities.

Therapeutic Uses of Alzamed

Main Uses of Alzamed

Alzamed is a medication primarily used for the symptomatic treatment of mild to moderately severe dementia in patients diagnosed with Alzheimer's disease. As a progressive neurological disorder, Alzheimer's disease leads to a gradual decline in cognitive functions, including memory, reasoning, and the ability to perform daily tasks.

The active component in Alzamed belongs to a class of drugs known as cholinesterase inhibitors. In the brains of individuals with Alzheimer's disease, there are lower levels of acetylcholine, a chemical messenger involved in memory and cognitive function. Alzamed works by reducing the breakdown of this substance, thereby increasing the concentration of acetylcholine available for nerve cell communication.

Potential Benefits

The primary goal of treatment with Alzamed is to manage the symptoms of dementia rather than to provide a cure for the underlying disease. The benefits observed can vary significantly between individuals, but generally include:

  • Cognitive Support: Many patients experience a temporary stabilization or a slower rate of decline in cognitive abilities, such as memory, orientation, and language.
  • Functional Maintenance: By managing cognitive symptoms, the medication may help patients maintain their ability to perform routine activities of daily living for a longer period.
  • Behavioral Stabilization: Improvements or stabilization in mood and behavioral symptoms associated with Alzheimer's disease may occur, which can contribute to a better quality of life for both the patient and their caregivers.

It is important to note that Alzamed does not alter the eventual progression of Alzheimer's disease. The effectiveness of the treatment is typically assessed periodically by healthcare professionals to determine if the medication continues to provide a therapeutic benefit.

Regulatory References

  1. NIH MedlinePlus overview on Donepezil

Eligibility and Restrictions for Use

Who can and cannot use Alzamed?

Eligibility for Alzamed (Donepezil) is strictly governed by regulatory documentation, which outlines the approved population, absolute contraindications, and required precautions for specific patient groups.


Contraindications and Exclusion

Category Status Details
Absolute Contraindication Prohibited Patients with known hypersensitivity (allergy) to Donepezil hydrochloride, piperidine derivatives, or any formulation excipients [FDA Label].
Pediatric Population Not Recommended Use in children and adolescents (under 18 years) is not recommended as safety and efficacy have not been established [SmPC].
Lactation Not Recommended Women taking Alzamed should not breastfeed as excretion into human milk is unknown, making it an excluded population [SmPC].

Conditional Use and Special Caution

Condition/Status Regulatory Rule
Cardiovascular Conditions Use with caution in patients with cardiac conduction abnormalities, such as Sick Sinus Syndrome or heart block [FDA Label].
Pulmonary/GI Conditions Caution is advised for patients with a history of asthma, obstructive pulmonary disease, or peptic ulcer disease [SmPC].
Hepatic Impairment Severe hepatic impairment patients are generally not recommended due to a lack of data, but use is allowed with caution in mild-to-moderate cases [SmPC].
Pregnancy Avoided unless clearly necessary; the potential risk to the human fetus is unknown as adequate clinical data are unavailable [SmPC].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding this medication identifies several classes of products that may interact, leading to changes in the drug's exposure or enhanced pharmacologic effects. These statements establish required constraints for co-administration.

Interaction Classification Relevant Medicinal Product Categories
Pharmacodynamic Overlap Risks Cholinergic Agents, Other Cholinesterase Inhibitors, Anticholinergics, NMDA Antagonists, L-Dopa, Dopaminergic Agonists, Antispasmodics (e.g., Dantrolene, Baclofen)
Exposure-Altering Substances CYP450 Enzyme Inhibitors/Inducers, Renal Cationic Transport Substrates, Oral Anticoagulants (e.g., Warfarin)

Interaction-Related Restrictions: Concomitant administration with other NMDA-receptor antagonists such as Amantadine, Ketamine, and Dextromethorphan should be avoided due to the potential for more frequent or pronounced adverse reactions. The effects of certain drugs, including L-dopa and dopaminergic agonists, may be enhanced, while the effects of barbiturates and neuroleptics may be reduced.

Official Interaction Statements: Co-administration with substances that use the same renal cationic transport system (e.g., Cimetidine, Quinidine) may increase drug plasma levels. Additionally, in patients receiving oral anticoagulants like Warfarin, close monitoring of Prothrombin Time or International Normalized Ratio (INR) is advised due to isolated post-marketing reports of INR increases. This structure defines the official constraints for safe co-prescribing.

Mechanism of Action

How Alzamed Works: Mechanism of Action

Alzamed's biological action involves a dual-target mechanism focused primarily on the central nervous system. First, the drug acts as a reversible inhibitor of acetylcholinesterase (AChE), the enzyme responsible for hydrolyzing the neurotransmitter acetylcholine (ACh). This inhibition increases the synaptic concentration and dwelling time of ACh, thereby augmenting cholinergic neurotransmission in neural circuits associated with memory and learning.

Second, the drug functions as a low-to-moderate affinity, non-competitive antagonist of the NMDA receptor. By selectively occupying a binding site within the receptor's ion channel, Alzamed modulates the excessive influx of calcium ( Ca^2+) ions that characterizes pathological overstimulation (excitotoxicity). This action contributes to the maintenance of neural circuit stability.

This integrated approach influences core intracellular pathways of neuroinflammation and protein homeostasis, including pathways related to Abeta and hyperphosphorylated Tau protein. The resulting physiological modulation supports synaptic plasticity and functional integrity within the central nervous system.

Dosage and Administration Information

Official Administration Guidelines for Alzamed (Memantine)

Alzamed (memantine) is administered via the oral route in tablet, extended-release (ER) capsule, or oral solution forms. The use of this medicine follows a specific titration protocol, which varies based on the formulation.


Dosing and Titration Schedules

Treatment is initiated at a low dose and increased in weekly increments to reach the full maintenance dose. The minimum interval between dose increases is one week.

Formulation Starting Dose Weekly Increment Target Maintenance Dose
Immediate-Release (IR) Tablet/Solution 5 mg once daily 5 mg 20 mg/day (e.g., 10 mg twice daily)
Extended-Release (ER) Capsule 7 mg once daily 7 mg 28 mg once daily

Administration Conditions and Constraints

The medicine can be taken with or without food. It is intended to be taken at the same time every day.

  • IR Tablets: Typically divided and taken twice daily upon reaching the maintenance phase.
  • ER Capsules: These are to be swallowed whole. Alternatively, the capsule may be opened and the entire contents sprinkled onto a spoonful of applesauce and swallowed immediately without chewing. The contents are not to be divided or crushed.

Special Populations and Missed Doses

For patients with severe renal impairment (CrCl 5–29 mL/min), the maximum dose is reduced to 10 mg per day for the IR form or 14 mg once daily for the ER form.

If a single dose is missed, the missed dose is skipped and the next scheduled dose is taken; the dose should not be doubled to compensate. If multiple doses are missed, treatment is not resumed without professional guidance.

Recent Clinical Evidence

Research evidence / Overview of Studies for Alzamed

Evidence for Use in Mild to Moderate Alzheimer's Disease

Alzamed (donepezil) was evaluated in people living with mild to moderate Alzheimer's disease (AD). Researchers primarily used short-term and intermediate-term randomized controlled trials (RCTs), where participants received either the medication or an inactive placebo. These studies were designed to evaluate how symptoms change over time when compared to placebo or other study arms. The studies monitored a variety of outcomes reflecting daily functioning or activity level, in addition to scores for cognitive function. Findings described patterns observed in the studies that were generally common across several short-term trials.

Despite these common findings, certainty remains low for long-term outcomes. Follow-up durations were limited in the most rigorous controlled studies, meaning that the evidence for how symptoms evolve over multiple years is less clear. Furthermore, outcomes related to physical discomfort or overall quality of life were observed in some studies, but the findings were mixed or had limited patterns.


Evidence for Use in Moderate to Severe Alzheimer's Disease

Research also examined the use of Alzamed in people with moderate to severe AD, a condition marked by functional limitations. Studies were conducted to examine the effect during periods of increased symptom activity and focused on assessing symptoms where functional ability scores are lower. Specialized scales were evaluated in this group to monitor changes in cognitive function and daily functioning. Findings described patterns observed in the studies related to the rate of change in functional ability. Data showed patterns related to monitoring physiological strain or stress, although the overall magnitude of the measurement was limited across the study period.

Long-term effects are not fully established for this population. Follow-up durations were limited in the controlled trial setting. Also, data are still emerging for certain groups, particularly concerning the full impact on behavioral symptoms and the experience of caregivers over long periods.


Evidence for Use in Dementia with Lewy Bodies (DLB)

Alzamed was studied for use in Dementia with Lewy Bodies (DLB), a condition characterized by fluctuating or episodic manifestations. The studies explored both cognitive change and specific non-cognitive outcomes, such as visual hallucinations and the periods of confusion associated with DLB. These trials were typically short-term, using comparisons against a placebo. A key limitation is that the sample sizes were modest in the main trials for DLB; therefore, results apply only to the populations studied. Evidence is limited for long-term outcomes, as the trials mostly focused on responses over defined time intervals of just a few months.

Key Studies & References A.14 Donepezil – Alzheimer disease – WHO Essential Medicines List Expert Review

Frequently Asked Questions (FAQ)

Common questions about Alzamed (FAQ)

Q: How quickly can someone expect to see benefits from taking Alzamed?

A: Studies and official information indicate that the medicine is absorbed slowly and takes several days to reach a steady level in the body. Clinical data suggests that it may take several weeks to a few months of consistent use to observe the potential effects on symptoms.

Q: Is Alzamed considered a long-term medication?

A: Yes, Alzamed is intended for the long-term management of the symptoms of the condition it treats. Although clinical studies often evaluate effects over periods of many months or years, the prescribing information supports its use as a continuous treatment.

Q: Are there any long-term side effects associated with Alzamed use?

A: Official safety data lists common side effects that are often temporary, as well as rare, serious adverse reactions that can occur. Official prescribing information states that the evidence for how symptoms evolve or for long-term outcomes remains limited in the most rigorous controlled studies.

Q: Does Alzamed interact with common pain relievers like ibuprofen?

A: Official regulatory documents do not specifically list common pain relievers like ibuprofen as prohibited. However, general caution is advised for co-administration. Both the cholinesterase inhibitor class (to which Alzamed belongs) and non-steroidal anti-inflammatory drugs (NSAIDs) carry an independent risk of gastrointestinal bleeding, which must be considered.

Q: What happens if I take Alzamed with an antidepressant?

A: Many antidepressants can affect the liver enzymes (CYP450) that process Alzamed, potentially changing the level of the medicine in the bloodstream. When co-administered with medications that affect these enzymes, close patient monitoring is generally advised by regulatory documents.

Q: Are there any foods or drinks that should be avoided while on Alzamed?

A: Official prescribing information states that Alzamed can be taken with or without food. There are no specific foods or drinks listed in the regulatory documents that must be completely avoided while taking this medicine.

Q: Can drinking alcohol be risky while taking Alzamed?

A: Caution is advised regarding the consumption of alcohol while taking Alzamed. This is because alcohol may increase the risk of central nervous system side effects associated with the medicine, such as dizziness, unsteadiness, or drowsiness.

Q: Is it safe for older adults over 75 to take Alzamed?

A: Alzamed is approved for use in adults with the specified condition, including older adults. Studies indicate that the way the body processes the medicine is generally similar across different age groups, but appropriate use is determined by a healthcare professional based on individual health factors.

Q: Is Alzamed safe to use if I have high blood pressure?

A: Official adverse event reports list both high blood pressure (hypertension) and low blood pressure (hypotension) among the possible side effects. Caution is required because Alzamed has the potential to affect heart rate and cardiovascular function, regardless of current blood pressure.

Q: Is there a generic version of Alzamed available yet?

A: Yes, regulatory agencies have approved generic versions of the active ingredient, Donepezil. This means that generic forms of the medicine are available in some formulations and strengths.

Q: What is the typical timeframe for how long Alzamed stays active in the body?

A: The medicine has a relatively long elimination half-life of approximately 70 hours. This is the amount of time it takes for half of the dose to be cleared from your system, which supports its standard once-daily dosing.

Q: What should I do if I accidentally miss a dose of Alzamed?

A: Official administration guidelines state that if a single dose is missed, the recommended procedure is to skip the missed dose and take the next dose at the regularly scheduled time. Doses should not be doubled to compensate.

Q: Why do some people stop taking Alzamed after they start it?

A: In clinical trials, the primary reasons for people stopping the medication included a lack of perceived benefit or experiencing unmanageable side effects. Regulatory information indicates that if treatment is discontinued, a gradual loss of the cognitive benefit that had been achieved may occur.

Q: Has Alzamed been approved in major countries outside of the US?

A: Yes, the medicine is authorized for use by major regulatory bodies globally, including the European Medicines Agency (EMA). This indicates its established international approval status for the conditions it treats.

Q: Is Alzamed safe to take with vitamins or herbal supplements?

A: Caution is advised for all supplements, as the official documents specifically warn about interactions with substances that affect the liver enzymes (CYP450) that process Alzamed. Certain herbal supplements, like St. John's wort, are known to interfere with these enzymes.

Q: Can people with a history of seizures take Alzamed?

A: Seizures are listed in the official documents as a serious adverse event associated with the use of Alzamed. For this reason, caution is generally advised when the medicine is prescribed to patients with a history of seizure disorders.

Q: Does Alzamed affect blood sugar levels?

A: Changes in blood glucose, specifically high blood sugar (hyperglycemia), have been reported as an uncommon event in regulatory safety data. However, the medicine is not primarily associated with effects on blood sugar regulation.

Q: How long has Alzamed been on the market?

A: The active ingredient in Alzamed (Donepezil) was first approved for use by the U.S. Food and Drug Administration (FDA) in 1996, meaning it has been a treatment option for decades.

Q: Does Alzamed cause weight gain or loss?

A: Official safety documents list anorexia (loss of appetite) and weight loss as common adverse effects associated with the use of the medicine. These are effects observed in clinical trials.

Q: Does Alzamed interact with over-the-counter cold and flu medicine?

A: Yes, specific ingredients in over-the-counter (OTC) medicines can interact. For example, the cough suppressant Dextromethorphan should be avoided. Also, many common OTC antihistamines have anticholinergic effects which can reduce Alzamed's effectiveness.

Q: What are the requirements for getting a prescription for Alzamed?

A: Alzamed is a prescription-only medicine. Regulatory documents state that it is indicated only for the specific conditions it was studied to treat. A healthcare professional must assess the patient against these criteria and confirm the absence of contraindications.

Q: Can young adults be prescribed Alzamed for other cognitive issues?

A: The official prescribing information indicates that the medicine is not recommended for use in the pediatric population (under 18 years) due to a lack of established safety and efficacy data. It is only approved for use in adults with the indicated conditions.

Q: Are there any warnings about operating machinery while on Alzamed?

A: Official warnings state that the medicine may cause side effects like dizziness, drowsiness, or blurred vision. Patients should not drive or operate complex machinery until they are aware of how the medicine affects them and their ability to perform these tasks.

Q: What is the percentage of people who respond well to Alzamed?

A: Clinical study data suggests that the percentage of people who show a beneficial response can vary widely. The official data defines 'response' based on various scores for cognitive improvement or functional stabilization, which leads to different rates of measured benefit.

How should Alzamed be stored and disposed of?

How to Store and Dispose of Alzamed? (Donepezil Hydrochloride)

Alzamed must be stored according to regulatory requirements to ensure its stability. Tablets and orally disintegrating tablets (ODT) should be kept at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F), away from excess heat and moisture. The transdermal system requires specific handling: unused sealed pouches must be stored in the refrigerator and allowed to reach room temperature before use.

Required Conditions

Storage Component Requirement
Temperature (Tablets/ODT) 20 C to 25 C
Container Rule Keep tightly closed and in original packaging
Child Safety Must be kept out of the reach of children

Disposal

Expired or unused Alzamed should be managed through a drug take-back program. If a program is unavailable, medication must be mixed with an unappealing substance, sealed in a bag, and discarded in the trash. Used transdermal systems must be folded adhesive-side-to-adhesive-side and placed in the trash; flushing any form of the medicine is prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alzamed found in:

A-Z Index: